Sort   by:  
 Page size 
GenomicsEGAD00000000045
Genomic sequencing and transcriptome shotgun sequencing of a metastatic tumour and its recurrence after drug therapy in a single patient
EGAD00000000045 | EGA
GenomicsEvolution of an adenomacarcinoma in response to selection by targeted kinase inhibitors
Background - Adenocarcinomas of the tongue are rare and represent the minority (20-25%) of salivary gland tumors affecting the tongue. We investigated the utility of massively parallel sequencing to characterize an adenocarcinoma of the tongue, before and after treatment. R...
EGAS00000000074 | EGA
GenomicsThe clonal and mutational evolution spectrum of primary triple negative breast cancers
Primary triple negative breast cancers (TNBC) represent approximately 16% of all breast cancers and are a tumour type defined by exclusion,for which comprehensive landscapes of somatic mutation have not been determined. Here we show in 104 early TNBC cases, that at the time of diagnosis these cancer...
EGAS00001000132 | EGA
UnknownPostoperative vascular complications in unrecognised Obstructive Sleep apnoea (POSA) study protocol: an observational cohort study in moderate-to-high risk patients undergoing non-cardiac surgery.
Not available
S-EPMC3902377 | biostudies-literature
GenomicsARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
We have sequenced the whole transcriptomes of 18 ovarian clear-cell carcinomas and 1 ovarian clear-cell carcinoma cell line and found somatic mutations in ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) in 6 of the samples. ARID1A encodes BAF250a, a key component of the SWI–SNF chromati...
EGAS00000000075 | EGA
GenomicsNational Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments

The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative seeks to accelerate research in novel marker and drug development, along with understanding the molecular basis of pediatric malignancy, through identification of genomic changes associated with the follo...

phs000218.v5.p1 | EGA
TranscriptomicsAXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Phosphoinositide-3-kinase (PI3K)-α inhibitors are clinically active in squamous carcinoma (SCC) of the head and neck (H&N) bearing mutations or amplification of PIK3CA. We aimed to identify potential mechanism of resistance and have observed that SCCs cells overcome the antitumor effects of the PI3K...
ORGANISM(S): Homo sapiens 
2015-04-12 | E-GEOD-61515 | biostudies-arrayexpress
GenomicsWhole genome sequencing - samples
Mutational landscapes of primary triple negative breast cancers - WGS
EGAD00001000115 | EGA
GenomicsRNA seq - samples
Mutational landscapes of primary triple negative breast cancers - RNA seq
EGAD00001000132 | EGA
GenomicsEGAD00010000148
tumour samples using Affymetrix Genome-Wide SNP6.0 arrays
EGAD00010000148 | EGA
Sort   by:  
 Page size